PMC9267161_01
Case 1: At presentation (a); after 4 weeks treatment with calcipotriol (50 mug/g)/betamethasone dipropionate (0.5 mg/g) (Cal/BD) foam (once daily) (b); and after 5 months Cal/BD foam (twice weekly) (c).
dic-2022-4-3-Figure1.jpg
PMC9267161_01_dic-2022-4-3-Figure1.jpg
f1-dic-2022-4-3
Lesions were localized on his scalp (Figure 1a) and legs. At 4 weeks, he had a PGA of 1, pruritus VAS of 0 and a DLQI of 3, and his scalp lesions were resolved (Figure 1b). At 6 months, PGA of 1 and pruritus VAS of 0 were unchanged, but the DLQI was further reduced to 2 (Figure 1c).
Case 2: at presentation (a); after 4 weeks treatment with calcipotriol (50 mug/g)/betamethasone dipropionate (0.5 mg/g) (Cal/BD) foam (once daily) (b); and after proactive management with Cal/BD foam (twice weekly) for 5 months (c) and 11 months (d).
dic-2022-4-3-Figure2.jpg
PMC9267161_01_dic-2022-4-3-Figure2.jpg
f2-dic-2022-4-3
Examination revealed scalp psoriasis with dandruff-like skin flaking (Figure 2a). After 4 weeks of Cal/BD foam treatment, both PASI and DLQI were reduced to 0, and scalp psoriasis was resolved (Figure 2b). DLQI remained at 0 and PASI had increased to 3 and was accompanied by the re-appearance of some dandruff-like skin flaking (Figure 2c). During the first 5 months of long-term treatment, the patient did not experience any relapse. The dandruff-like skin flaking on the scalp had disappeared (Figure 2d).
PMC9267161_02
Case 3: at presentation (a); after 4 weeks treatment with calcipotriol (50 mug/g)/betamethasone dipropionate (0.5 mg/g) (Cal/BD) foam (once daily) (b); after 4 months Cal/BD foam (twice weekly) (c); and after 2 months without any treatment (d).
dic-2022-4-3-Figure3.jpg
PMC9267161_02_dic-2022-4-3-Figure3.jpg
f3-dic-2022-4-3
She presented with trunk lesions (Figure 3a) and had a PGA of 3 and a DLQI of 6. PGA score to 1 and DLQI to 0. Proactive management with Cal/BD foam (twice per week) for 4 months reduced PGA to 0 and DLQI remained at 0, with the disappearance of the vitiligous lesion (Figure 3c). The patient's reason for stopping the treatment was that she had observed a high effectiveness in the initial therapy phase in the first period of long-term treatment and thought that this effectiveness would be maintained even without treatment (Figure 3d).
PMC9267161_03
Case 4: at presentation (a) and at 4 months after initial presentation [initial therapy: 4 weeks' treatment with calcipotriol (50 mug/g)/betamethasone dipropionate (0.5 mg/g) foam (once daily), followed by proactive maintenance therapy: 3 months Cal/BD foam (twice weekly)] (b).
dic-2022-4-3-Figure4.jpg
PMC9267161_03_dic-2022-4-3-Figure4.jpg
f4-dic-2022-4-3
At presentation, she had a PASI of 4.2 and DLQI of 6, with lesions present on both elbows and trunk (Figure 4a). Lesions were resolved following daily treatment and maintained during proactive management (Figure 4b) and were accompanied by reductions of both PASI and DLQI to 0.